许斌
肿瘤
副教授，副主任医师，硕士生导师，医学博士
副教授，副主任医师，硕士生导师，医学博士
导师介绍
| 姓名 | 许斌 |
| 出生年月 | 1987年3月 |
| 单位 | 武汉大学人民医院肿瘤一科 |
| 所属学科 | 临床医学-肿瘤学 |
| 职务、职称及头衔 | 副教授，副主任医师，硕士生导师,医学博士 |
| xubin_oncology@whu.edu.cn | |
| 联系方式 | 027-88041911转82281或18963940661 |
| 研究方向 |
1.肺癌的基础与临床转化研究 2.肿瘤免疫微环境与精准治疗 |
| 个人简介 | 主要从事恶性肿瘤的诊治与科研、教学工作，目前主持及参与国自然、省自然、省科协、武汉大学项目、横向课题等科研项目十余项，并参与多项国际、国内多中心临床研究。获湖北省科技进步奖二等奖。在柳叶刀子刊《eBioMedicine》、自然旗下《oncogene》等中英文杂志发表数十篇代表性论文，在ASCO/CSCO等国内外大型会议发表重要研究成果，主编/参编多部著作，其中人民卫生出版社2部。已参与培养硕士生5名，博士生3名。 |
| 学术任职与荣誉 |
1.全国及湖北省“青年文明号”号长 2.中国临床肿瘤学会“35 under 35”优秀青年肿瘤医生 3.中国医师协会医学家峰会全国十大医学新锐 4.湖北省临床肿瘤学会健康教育专家委员会主任委员 5.武汉医学会放射肿瘤治疗学分会青年专家委员会主任委员 6.湖北省医学生物免疫学会胸部肿瘤多学科协作专家委员会副主任委员 7.湖北省抗癌协会肿瘤免疫治疗专委会青年委员会副主任委员 8.湖北省科学技术厅科技专家库高端专家 9.武汉市科技局专家库成员 10.中国老年保健协会医学可视化专业委员会委员 11.中国初级卫生保健基金会肺部肿瘤慢性病专业委员会委员 12.中国初级卫生保健基金会胸部肿瘤精准治疗专业委员会委员 |
| 教育履历 |
2004.09-2011.06武汉大学第一临床学院临床医学专业七年制获硕士学位 2013.09-2016.11武汉大学第一临床学院内科学博士研究生获博士学位 |
| 工作履历 |
2011.07-2014.05武汉大学人民医院肿瘤一科 住院医师 2014.06-2020.11武汉大学人民医院肿瘤一科 主治医师 2020.12-至今武汉大学人民医院肿瘤一科 副主任医师 |
| 成果获奖 |
1.靶向及智能放疗质控体系创新与应用，2020年湖北省科技进步二等奖 2.肿瘤免疫治疗药物开发现状及展望，2022年知网高下载论文 3.2014年中华医学会医学教育分会及中国高等教育学会医学教育专业委员会“2013年度医学教育百篇优秀论文评选”三等奖 4.2019年湖北省医学会放射肿瘤治疗学分会“年会优秀论文”二等奖 |
| 代表性论著 |
1. Zuo
Y, Zhong J, Bai H, Xu B et al. Genomic and epigenomic profiles distinguish
pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
EBioMedicine. 2022 Aug;82:104165.（共一；一区Top；IF
11.205） 2. Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, Xu B. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.[J] .Oncogene, 2021, 40: 4413-4424. (通讯；一区Top；IF 9.867) 3. Wu J, Li L, Wu S, Xu B. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value. Cancer Biol Med. 2020 Aug 15;17(3):528-542. (通讯；一区Top；IF 4.248) 4. Zhang H, Yao Y, Wu J, Zhou J, Zhao C, He J, Xu B. Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. Front Immunol. 2022 Jul 18;13:838374. (通讯；二区Top；IF 8.787) 5. Zhu L, Ye D, Lei T, Wu J, Wang W, Xu B. Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Rev Mol Med. 2022 Apr 4;24:e16. (共通讯；二区；IF 7.615) 6. Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H, Lei T, Xu B. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front Microbiol. 2021 Jul 21;12:707290. (通讯；二区Top；IF 6.064) 7. Xu B, Song KH, Yao Y, et al. Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Sci. 2021 Jun;112(6):2522-2532. (共一；二区；IF 6.518) 8. Wu J, Zhang H, Li L, Hu M, Chen L, Wu S, Xu B, Song Q. Prognostic nomogram for predicting survival in patients with high grade endometrial stromal sarcoma: a Surveillance Epidemiology, and End Results database analysis. Int J Gynecol Cancer. 2020 Oct;30(10):1520-1527. (共通讯；三区；IF 3.437) 9. Zhao Y, Wu J, Li L, Zhang H, Zhang H, Li J, Zhong H, Lei T, Jin Y, Xu B，Song Q. Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. Front Genet. 2022 Feb 10;13:820135.（共通讯；三区；IF 4.559） |
| Name | BIN XU |
| Date of birth | Mar，1987 |
| Department | Oncology Department，Renmin Hospital,Wuhan University. |
| Title | Associate Chief Physician, Master Tutor |
| xubin_oncology@whu.edu.cn | |
| TEL | 027-88041911转82281或18963940661 |
| Research Direction |
1.basis
and clinical translation research of lung cancer 2. tumor microenvironment and precision therapy |
| Personal Profile | His team is mainly engaged in the diagnosis and treatment and scientific research of cancer. His research direction is to carry out basis and clinical translation research of lung cancer and investigate the tumor immune microenvironment for precision therapy. His research has been supported by more than ten scientific research projects such as 3 items of the National Natural Science Foundation of China, 1 items of the Hubei Provincia Natural Science Foundationfrom, 1 items of Hubei Provincial Science and Technology Association, and other Wuhan University Project or horizontal projects. He has participated in many international and domestic clinical research. He has won the second prize of Hubei Province Science and Technology Progress Award. He has published dozens of representative papers in top magazines such as In the Lancet "ebiomedicine" and the Nature "Oncogene", as the first author or corresponding author.He has participated in the editing of “Practice and Progress in Standardized Diagnosis and Treatment of Clinical Oncology (Lung Cancer Volume)” and several other multiple works, including 2 People’s Publishing House. Five master students and three doctoral students are being under his training. |
| Selected Publications |
1. Zuo
Y, Zhong J, Bai H, Xu B et al. Genomic and epigenomic profiles distinguish
pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
EBioMedicine. 2022 Aug;82:104165.（共一；一区Top；IF
11.205） 2. Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, Xu B. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.[J] .Oncogene, 2021, 40: 4413-4424. (通讯；一区Top；IF 9.867) 3. Wu J, Li L, Wu S, Xu B. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value. Cancer Biol Med. 2020 Aug 15;17(3):528-542. (通讯；一区Top；IF 4.248) 4. Zhang H, Yao Y, Wu J, Zhou J, Zhao C, He J, Xu B. Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. Front Immunol. 2022 Jul 18;13:838374. (通讯；二区Top；IF 8.787) 5. Zhu L, Ye D, Lei T, Wu J, Wang W, Xu B. Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Rev Mol Med. 2022 Apr 4;24:e16. (共通讯；二区；IF 7.615) 6. Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H, Lei T, Xu B. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front Microbiol. 2021 Jul 21;12:707290. (通讯；二区Top；IF 6.064) 7. Xu B, Song KH, Yao Y, et al. Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Sci. 2021 Jun;112(6):2522-2532. (共一；二区；IF 6.518) 8. Wu J, Zhang H, Li L, Hu M, Chen L, Wu S, Xu B, Song Q. Prognostic nomogram for predicting survival in patients with high grade endometrial stromal sarcoma: a Surveillance Epidemiology, and End Results database analysis. Int J Gynecol Cancer. 2020 Oct;30(10):1520-1527. (共通讯；三区；IF 3.437) 9. Zhao Y, Wu J, Li L, Zhang H, Zhang H, Li J, Zhong H, Lei T, Jin Y, Xu B，Song Q. Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. Front Genet. 2022 Feb 10;13:820135.（共通讯；三区；IF 4.559） |
武汉大学人民医院
湖北省人民医院